Shilpa Pharma Lifesciences’ Unit 2 Raichur has cleared the ANVISA-Brazil GMP inspection

The Unit has been issued GMP Certification from ANVISA-Brazil

Biocon inks agreement for Ozempic commercialization in Brazil with Biomm

Biocon will undertake the development, manufacturing and supply of the drug product, and Biomm will be responsible for obtaining regulatory approval and commercialization in the Brazilian market

Cupid to supply Rs. 23.07 crore female condoms in Brazil

Total value of the supplies of FC will be US$ 2.773 million

Supriya Lifesciences received GMP certification from ANVISA Brazil

The clearance of this audit marks the successful registration of 8 APIs with CADIFA

Gufic Biosciences receives TGA Australia and ANVISA Brazil approval for Parecoxib 40mg injection

Parecoxib Sodium is the first parenteral selective COX-2 inhibitor available for clinical use in pain management

Hikal receives Brazilian GMP certification and USFDA EIR for Bangalore and Panoli facilities

Mitsui Chemicals ‘Super-Bond’ dental adhesive to launch in Brazil

Super-Bond is made up of a polymerization initiator, a liquid and a polymer powder

SeQuent Scientific completes acquisition of Nourrie in Brazil

Brazil has the 4th largest pet market in the world with an estimated market size of BRL 1.8 billion, growing annually at 16%

Lupin and Biomm tie-up for pegfilgrastim in Brazil

Lupin had earlier received the U.S. FDA acceptance of the Biologics License Application (BLA) for Its proposed biosimilar

Brazil’s Eurofarma to manufacture Comirnaty for Latin America

The manufacture of finished doses will commence in 2022 and at full operational capacity, the annual production is expected to exceed 100 million doses annually